What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce and provide details regarding Abbott Laboratories' financial results for the third quarter of 2025, as well as to furnish the accompanying press release.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide investors with a clearer view of the company's ongoing operational performance by adjusting for factors that may be unusual, unpredictable, or not reflective of core business activities, such as acquisition-related costs and restructuring charges.

What specific items are excluded from Abbott's non-GAAP measures?

Abbott's non-GAAP measures typically exclude expenses related to acquisitions, restructuring actions, fair value adjustments to contingent consideration, certain regulatory costs, adjustments related to deferred tax benefits, and excess tax benefits associated with share-based compensation, among others.

How should investors interpret Abbott's non-GAAP financial results?

Investors should consider Abbott's non-GAAP financial measures in conjunction with, and not as a replacement for, the financial measures prepared in accordance with GAAP. The press release furnished with this 8-K should provide a reconciliation between GAAP and non-GAAP figures, allowing for a comprehensive understanding of the company's financial performance.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) has filed an 8-K report detailing its financial results for the third quarter of 2025, announced on October 15, 2025. The filing includes a press release that presents both GAAP and non-GAAP financial measures. Investors should pay close attention to the company's use of non-GAAP figures, which exclude items such as acquisition-related expenses, restructuring costs, contingent consideration adjustments, certain regulatory costs, and tax-related adjustments. Abbott's management utilizes these non-GAAP measures to offer a clearer view of ongoing operational performance by adjusting for unusual or unpredictable factors. While these measures are intended to provide greater visibility into core business results, it is crucial for investors to consider them alongside the company's GAAP-reported financials. The press release, furnished as an exhibit, will contain the specific details of these financial outcomes and the reconciliation of non-GAAP to GAAP figures.

Key Highlights

1Abbott Laboratories announced its third quarter 2025 financial results on October 15, 2025.
2The 8-K filing includes a press release (Exhibit 99.1) detailing the company's performance for the quarter.
3Abbott utilizes non-GAAP financial measures to report results, adjusting for specific items like acquisition costs and restructuring charges.
4The company believes these non-GAAP measures offer better insight into ongoing operational performance.
5Key exclusions from non-GAAP measures include expenses related to acquisitions, fair value adjustments to contingent consideration, and certain tax benefits/adjustments.
6Abbott emphasizes that non-GAAP measures should be considered in addition to, not as a substitute for, GAAP financial measures.
7The filing also includes the Cover Page Interactive Data File in XBRL format.

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 15, 2025)

Summary

Key Highlights

Frequently Asked Questions